RepoCeuticals has developed a medicinal product (skin cream) for the prevention and treatment of radiation damage due to radiotherapy for breast cancer.
RepoCeuticals’ skin cream is expected to have a relevant therapeutic effect to prevent and treat radiation damage to the breast region resulting from radiotherapy after an operation for breast cancer, by topical application to the skin.
RepoCeuticals has initiated a clinical trial in collaboration with Danish University Hospitals to assess its efficacy in preventing and alleviating radiation dermatitis by application to the breast area or upper torso.
Breast cancer is the most common cancer affecting women worldwide. Radiation dermatitis affects nearly all women receiving radiotherapy for breast cancer.
External radiotherapy for breast cancer.
Over 500,000 new cases of breast cancer are estimated in 2017 for the US and Europe. Depending on the type of breast cancer and other circumstances, patients will undergo 30-40 radiation doses. RepoCeuticals’ protective melatonin skin cream should be used before each treatment and possibly for a given period after the last treatment.